Skip to main
SGRY

Surgery Partners (SGRY) Stock Forecast & Price Target

Surgery Partners (SGRY) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Surgery Partners is well-positioned for future growth with their integrated outpatient care model and recent divestiture that will improve their cash conversion and reduce leverage. The company's focus on high-acuity procedures and their track record of successful physician recruitment further supports their growth potential. While there are risks in the healthcare industry such as labor shortages and reimbursement challenges, Surgery Partners has a solid financial foundation and significant upside potential.

Bears say

Surgery Partners is facing multiple risks, including its high leverage and potential wage inflation due to competition for clinical labor. In addition, the company may not meet investor expectations for volume and revenue growth, and a potential recession could negatively impact its business. The recent divestiture of its Idaho Falls facilities may improve its margin profile, but the transaction is still pending approval. The company has shown strong share gain and has potential for margin expansion, but its margins may still fall below peers due to its lower exposure to higher-margin ASCs. Given these factors, our outlook on the company's stock is negative.

Surgery Partners (SGRY) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surgery Partners and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surgery Partners (SGRY) Forecast

Analysts have given Surgery Partners (SGRY) a Buy based on their latest research and market trends.

According to 8 analysts, Surgery Partners (SGRY) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surgery Partners (SGRY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.